Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a high-quality asset that complements our existing pipeline of targeted cancer therapies,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We believe tha